FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912291281> ?p ?o ?g. }

• W2912291281 endingPage "1682" @default.
• W2912291281 startingPage "1674" @default.
• W2912291281 abstract "Background Stopping tyrosine kinase inhibitor (TKI) treatment has become a realistic and safe objective for patients who have chronic myeloid leukemia (CML). Both a sustained deep molecular response (sDMR) and the lack of a molecular recurrence after TKI discontinuation are required to reach a durable treatment‐free remission (TFR). Methods The potential predictive role of BCR‐ABL transcripts in attaining an sDMR and a TFR was analyzed in a strictly consecutive, unselected series of 194 patients who were diagnosed and treated with TKIs at the authors’ center. Results Of 173 fully evaluable patients, 67 (38.7%) had the e13a2 transcript, and 106 (61.3%) had the e14a2 transcript. Complete cytogenetic and major molecular remissions were not affected, whereas the achievement of both a DMR ( P = .008) and an sDMR ( P = .004) was favored significantly in patients who had the e14a2 transcript. After a median of 68 months, the sDMR rate was 39.6% in those with the e14a2 transcript and 19.4% in those with the e13a2 transcript. In addition to transcript type, both the early achievement of a molecular response and starting treatment with a second‐generation TKI positively affected the attainment of an sDMR in multivariate analysis. The use of a second‐generation TKI as frontline treatment increased the sDMR rate in both transcript types. However, in patients who had the e13a2 transcript, the probability of attaining an sDMR was 37% after 60 months and did not increase further despite continuing therapy. Among 51 of 60 patients who attained an sDMR after discontinuing TKIs, 24 experienced a molecular relapse, but all regained molecular remission after resuming TKI treatment. Again, transcript type influenced TFR maintenance ( P = .005), because only 2 patients (3%) with the e13a2 transcript enjoyed a durable TFR compared with 25 (23.5%) of those with the e14a2 transcript. Conclusions The e13a2 transcript hinders the achievement of deep responses and the possibility of stopping TKI treatment in patients with CML." @default.
• W2912291281 created "2019-02-21" @default.
• W2912291281 creator A5008896098 @default.
• W2912291281 creator A5013731265 @default.
• W2912291281 creator A5020086659 @default.
• W2912291281 creator A5020124946 @default.
• W2912291281 creator A5026990551 @default.
• W2912291281 creator A5028460878 @default.
• W2912291281 creator A5029239024 @default.
• W2912291281 creator A5038660271 @default.
• W2912291281 creator A5050369634 @default.
• W2912291281 creator A5065443409 @default.
• W2912291281 creator A5066137729 @default.
• W2912291281 creator A5068459860 @default.
• W2912291281 creator A5069887195 @default.
• W2912291281 creator A5076236981 @default.
• W2912291281 creator A5076414242 @default.
• W2912291281 date "2019-02-01" @default.
• W2912291281 modified "2023-10-12" @default.
• W2912291281 title "The e13a2 BCR‐ABL transcript negatively affects sustained deep molecular response and the achievement of treatment‐free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors" @default.
• W2912291281 cites W1968747503 @default.
• W2912291281 cites W1969747807 @default.
• W2912291281 cites W2016656445 @default.
• W2912291281 cites W2030615871 @default.
• W2912291281 cites W2036862498 @default.
• W2912291281 cites W2041053839 @default.
• W2912291281 cites W2064367288 @default.
• W2912291281 cites W2072703295 @default.
• W2912291281 cites W2082580993 @default.
• W2912291281 cites W2117356576 @default.
• W2912291281 cites W2122487233 @default.
• W2912291281 cites W2189113171 @default.
• W2912291281 cites W2313607879 @default.
• W2912291281 cites W2407926436 @default.
• W2912291281 cites W2410606477 @default.
• W2912291281 cites W2528188718 @default.
• W2912291281 cites W2557854027 @default.
• W2912291281 cites W2564749987 @default.
• W2912291281 cites W2571877314 @default.
• W2912291281 cites W2590307110 @default.
• W2912291281 cites W2611148826 @default.
• W2912291281 cites W2613458149 @default.
• W2912291281 cites W2615706081 @default.
• W2912291281 cites W2626362851 @default.
• W2912291281 cites W2724649189 @default.
• W2912291281 cites W2778957910 @default.
• W2912291281 cites W2780178948 @default.
• W2912291281 cites W2792384496 @default.
• W2912291281 cites W2793387867 @default.
• W2912291281 cites W2980009032 @default.
• W2912291281 cites W4294307875 @default.
• W2912291281 doi "https://doi.org/10.1002/cncr.31977" @default.
• W2912291281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30707758" @default.
• W2912291281 hasPublicationYear "2019" @default.
• W2912291281 type Work @default.
• W2912291281 sameAs 2912291281 @default.
• W2912291281 citedByCount "40" @default.
• W2912291281 countsByYear W29122912812019 @default.
• W2912291281 countsByYear W29122912812020 @default.
• W2912291281 countsByYear W29122912812021 @default.
• W2912291281 countsByYear W29122912812022 @default.
• W2912291281 countsByYear W29122912812023 @default.
• W2912291281 crossrefType "journal-article" @default.
• W2912291281 hasAuthorship W2912291281A5008896098 @default.
• W2912291281 hasAuthorship W2912291281A5013731265 @default.
• W2912291281 hasAuthorship W2912291281A5020086659 @default.
• W2912291281 hasAuthorship W2912291281A5020124946 @default.
• W2912291281 hasAuthorship W2912291281A5026990551 @default.
• W2912291281 hasAuthorship W2912291281A5028460878 @default.
• W2912291281 hasAuthorship W2912291281A5029239024 @default.
• W2912291281 hasAuthorship W2912291281A5038660271 @default.
• W2912291281 hasAuthorship W2912291281A5050369634 @default.
• W2912291281 hasAuthorship W2912291281A5065443409 @default.
• W2912291281 hasAuthorship W2912291281A5066137729 @default.
• W2912291281 hasAuthorship W2912291281A5068459860 @default.
• W2912291281 hasAuthorship W2912291281A5069887195 @default.
• W2912291281 hasAuthorship W2912291281A5076236981 @default.
• W2912291281 hasAuthorship W2912291281A5076414242 @default.
• W2912291281 hasBestOaLocation W29122912811 @default.
• W2912291281 hasConcept C121608353 @default.
• W2912291281 hasConcept C126322002 @default.
• W2912291281 hasConcept C143998085 @default.
• W2912291281 hasConcept C170493617 @default.
• W2912291281 hasConcept C203014093 @default.
• W2912291281 hasConcept C2778715236 @default.
• W2912291281 hasConcept C2778729363 @default.
• W2912291281 hasConcept C2778820342 @default.
• W2912291281 hasConcept C42362537 @default.
• W2912291281 hasConcept C43907098 @default.
• W2912291281 hasConcept C71924100 @default.
• W2912291281 hasConceptScore W2912291281C121608353 @default.
• W2912291281 hasConceptScore W2912291281C126322002 @default.
• W2912291281 hasConceptScore W2912291281C143998085 @default.
• W2912291281 hasConceptScore W2912291281C170493617 @default.
• W2912291281 hasConceptScore W2912291281C203014093 @default.
• W2912291281 hasConceptScore W2912291281C2778715236 @default.
• W2912291281 hasConceptScore W2912291281C2778729363 @default.
• W2912291281 hasConceptScore W2912291281C2778820342 @default.

• next